Median Technologies Partners With Leading U.S. Healthcare Company to Bring eyonis® LCS to Patients Across the U.S. and Europe

About this update from Median Technologies

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1240,"height":461,"url":"https://media.zenfs.com/en/business-wire.com/cd90c42b8efa50fb73537ea082015224"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/n3BgoYmXtmBri9eZdeLytQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTM1NztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/cd90c42b8efa50fb73537ea082015224","width":960,"height":357},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/m738wMOFjt9.WSoxrSuVGQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD04OTI7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/cd90c42b8efa50fb73537ea082015224","width":1200,"height":446}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Non-exclusive commercial agreement for the distribution of eyonis® LCS in the United States and Europe","length":102,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"The agreement will become effective upon FDA 510(k) clearance","length":61,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Partner’s robust infrastructure and broad market reach in both the U.S. and Europe will maximize commercial launch","length":114,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":277,"olType":false},{"type":"text","content":"SOPHIA ANTIPOLIS, France, December 08, 2025--(BUSINESS WIRE)--Regulatory News:","length":78,"tagName":"p"},{"type":"text","content":"Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company"), manufacturer of eyonis® , a suite of artificial intelligence (AI) powered Software as a Medical Device (SaMD) for early cancer diagnosis, and a globally leading provider of AI-based image analyses and central imaging services for oncology drug developers, today announced the signing of a non-exclusive global commercial distribution agreement with a leading US healthcare company. The agreement covers the future commercialization of eyonis® LCS, Median’s AI-based SaMD for lung cancer.","length":602,"tagName":"p"},{"type":"text","content":"The collaboration will leverage the commercial partner’s robust infrastructure and broad market reach in both the U.S. and Europe to ensure efficient distribution of eyonis® LCS, once regulatory clearances are granted in the U.S., th...

More updates from Median Technologies